A recombinant version of oxalate decarboxylase, called A0, which is being developed by Captozyme, Inc could give hope to patients with oxalosis and hyperoxaluria, according to a study presented at the World Congress of Endourology (WCE) in Paris, France. This is great news for organizations such as the The Oxalosis and Hyperoxaluria Foundation, working to help these patients.
Captozyme, Inc. announced today that it is initiating a prospective double-blind, randomized, placebo controlled, cross-over study, with Nephure™, an oxalate reducing enzyme, to determine the extent to which Nephure vs. placebo reduces urinary oxalate excretion (mg/24 hour) in healthy subjects who are provided a controlled diet.
After working with the Burdock Group to recently obtain a successful self-contained GRAS (Generally Recognized As Safe) determination for its oxalate-reducing enzyme, biotechnology company Captozyme licensed the rights for commercialization to Entring LLC, which will make it available for purchase this fall as a food ingredient. Consumers seeking a low-oxalate diet can add the virtually tasteless, odorless powder to a variety of oxalate-packed foods and beverages to help reduce the presence of the anti-nutrient.
Helena Cowley, CEO of Captozyme, which was named a GrowFL Company To Watch in 2017, was the company's first employee. She never set out to be an entrepreneur, but says the process of growing the company has certainly turned her into one.
Captozyme, a Gainesville-based biotechnology company, is among 50 statewide companies expected to see significant growth over the next several years. Captozyme was selected from more than 500 nominees for Florida Companies to WatchSM, a statewide program managed by economic development group GrowFL, in association with the Edward Lowe Foundation.